International Biotechnology (Ordinary Share) IBT

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV


Share Price


Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
International Biotechnology (Ordinary Share) Price 19.89%
International Biotechnology (Ordinary Share) NAV 13.47%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement


Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 620.0 -6.1% 660.00 671.00
20 Jun

Discrete performance % over

Fund / BenchmarkJul '15
Jun '16
Jul '16
Jun '17
Jul '17
Jun '18
International Biotechnology (Ordinary Share) Price-22.6042.728.53
International Biotechnology (Ordinary Share) NAV-22.1841.662.94

Discrete performance over

Discrete Performance

Top 10 Holdings

Array 4.46%
Celgene Corporation 3.99%
Biogen Idec Inc., 3.99%
Neurocrine Biosciences, Inc. 3.99%
Genmab 3.51%
Regeneron Pharmaceuticals, Inc. 3.51%
Sage 3.42%
Vertex Pharmaceuticals 3.42%
Gilead Sciences Inc 3.13%
Exelixis, Inc. 3.04%

Sectors weighting

Biotechnology 105.40%
Net Current Assets -5.40%

Regional weighting

North America Region 89.00%
Europe Developed ex-UK 10.00%
UK 4.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 31 Mar 1994
  • Currency GBX
  • Domicile UK
  • Share Price 635.20
  • Share Type Ordinary Share
  • ISIN GB0004559349
  • Shares Issued (M) 38
  • Market Capital (£M) 232.80
  • Gross Assets (£M) 249.50
  • Net Assets (£M) 249.50
  • TER (%) 1.40
  • Last AGM 12 Dec 2017
  • Next AGM 12 Dec 2018
  • Last Annual Report Date 06 Nov 2017
  • Next due Report Date 28 Feb 2018
  • Next due Report Type I/R
  • Objective:

    To achieve capital growth through investing in high growth, development stage biotechnology companies.

  • Management Group(s):

  • SV Health Managers
  • Managed by:

  • Ailsa Craig Start: 01 Mar 2008
  • Carl Harald Janson Start: 02 Sep 2013
  • Kate Bingham Start: 01 Nov 2000
  • Management Contract & Fees:

    The Manager is entitled to a management fee payable monthly at 0.9% p.a. of the Company's NAV. The Investment Manager is entitled to an annual performance fee calculated as follows: The portfolio consists of two pools: quoted and unquoted. The fee on the quoted pool is 10% of relative outperformance above the pound sterling adjusted NASDAQ Biotech Index (£ NBI) plus a 0.5% hurdle. The fee on the unquoted pool is 20% of net realised gains, taking into account any unrealised losses but not unrealised gains. The payment of the performance fee is subject to the following limits: the maximum performance fee in any one year is 2% of the net assets as at the financial year end for the relevant period (the Performance Fee Cap). This Performance Fee Cap will be split pro-rata between the quoted and unquoted pool. Any performance fee that is earned in excess of the Performance Fee Cap in any performance period is carried forward and, in the case of the quoted pool proportion, used to offset future underperformance of the quoted portfolio for the current financial period plus two preceding periods. On termination of the Investment Manager other than for cause, any unpaid performance fees will become payable, subject to a cap of 4% of net assets for the performance period in which the Investment Manager's appointment is terminated. This will allow the Investment Manager to be paid any historic fees that were previously deferred. The performance fee will no longer be subject to a high water mark on the quoted portfolio. If after accounting for any carried forward underperformance and adding back any carried forward performance fees in a particular period, the current period's performance is still negative, no performance fee will be payable in that period. The Management Agreement is terminable by either party on 12 months' notice.